close
MENU
Tech & Innovation
7 mins to read

AFT Pharmaceuticals hopes to get US Maxigesic sales by early 2024

Shares rise after record FY23 results, maiden dividend declared. 

AFT Pharmaceuticals managing director Hartley Atkinson.

NZX-listed AFT Pharmaceuticals has declared a maiden dividend after record revenue to the end of March 2023, as it looks to start selling its flagship pain relief product Maxigesic into the US market early next year.

The Auckland-based pharmaceutical company’s share price surged 9% in early

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Fiona Rotherham Mon, 22 May 2023
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
AFT Pharmaceuticals hopes to get US Maxigesic sales by early 2024
Tech & Innovation,
99163
true